|
|
Volumn 28, Issue 28, 2010, Pages 4293-4295
|
|
Human epidermal growth factor receptor 2 testing in 2010: Does chromosome 17 centromere copy number make any difference?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
LAPATINIB;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
QUINAZOLINE DERIVATIVE;
BREAST CANCER;
CANCER RELAPSE;
CENTROMERE;
CHROMOSOME 17;
CLINICAL TRIAL (TOPIC);
DIAGNOSTIC TEST;
DRUG TARGETING;
EDITORIAL;
FALSE NEGATIVE RESULT;
FALSE POSITIVE RESULT;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE AMPLIFICATION;
GENE DOSAGE;
GENETIC SCREENING;
HUMAN;
IMMUNOHISTOCHEMISTRY;
INTRADUCTAL CARCINOMA;
PRIORITY JOURNAL;
UNSPECIFIED SIDE EFFECT;
BREAST TUMOR;
CLINICAL TRIAL;
FEMALE;
GENETICS;
LABORATORY DIAGNOSIS;
NOTE;
PRACTICE GUIDELINE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CENTROMERE;
CHROMOSOMES, HUMAN, PAIR 17;
CLINICAL TRIALS AS TOPIC;
FALSE NEGATIVE REACTIONS;
FALSE POSITIVE REACTIONS;
FEMALE;
HUMANS;
IMMUNOHISTOCHEMISTRY;
PRACTICE GUIDELINES AS TOPIC;
QUINAZOLINES;
RECEPTOR, ERBB-2;
|
|
EID: 78049436603
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2010.29.6673 Document Type: Editorial |
|
Times cited : (23)
|
|
References (8)
|
